The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases disorders and/or injuries. In one aspect the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.